RTX Corp (RTX) Stock News

ASUS announced new ProArt P16 and P14 laptops and GR1X mini PC powered by NVIDIA RTX Spark, featuring up to 128GB unified memory and designed for AI-powered creators and developers. The devices support local AI capabilities including 120B-parameter LLMs and 4K AI video generation, with exclusive ASUS applications like MuseTree and StoryCube for agentic AI workflows. The company also showcased Zenbook 14 and ExpertBook Ultra models at its IFA 2026 Media Showroom in Berlin.

RTX reported a $289 billion backlog with 22% year-over-year growth, driven by strong commercial aerospace (60%) and defense (40%) orders. The company posted 14% revenue growth to $24.7 billion in Q2 and recently secured a $22.9 billion seven-year Tomahawk cruise missile contract, supporting guidance of $95-96 billion in annual sales.

Escalating U.S.-Iran tensions in the Middle East, including strikes on Iranian rocket launchers and retaliatory attacks, are creating investment opportunities in the defense sector. Major defense contractors like Lockheed Martin, RTX, and Northrop Grumman are positioned to benefit from increased demand for military equipment and multi-billion-dollar procurement contracts. Defense ETFs offer diversified exposure to the industry as an alternative to individual stock investments.

XORTX Therapeutics has terminated its US$2.5 million investor relations and marketing agreement with IR Agency LLC effective August 7, 2026, with all funds returned to the company. The decision was made to postpone the IR program during the company's voluntary delisting from the TSX Venture Exchange, expected to take effect September 1, 2026. The company aims to reduce regulatory complexity and focus resources on clinical development. Additionally, XORTX disclosed previously omitted finder's fees of US$240,000 related to its April 2026 acquisition of Vectus Biosystems' Renal Anti-Fibrotic Therapeutic Program.

RTX's growing $289 billion backlog, driven by surging orders in both commercial aerospace and defense sectors, is a key indicator of future revenue and earnings growth. The backlog provides earnings visibility, de-risks the business from economic weakness, and drives long-term growth through profitable aftermarket services and recurring revenue. Management projects 2026 adjusted sales of $95-96 billion, with backlog growth dependent on orders exceeding sales growth.

Lockheed Martin, RTX lift 2026 forecasts as Pentagon looks to restock weapons  Reuters

The article compares two major defense contractors: Lockheed Martin, which relies heavily on the F-35 program and U.S. government contracts (72% of sales), and RTX, which offers more diversification through commercial and military aerospace segments. Lockheed Martin is recommended as the better buy due to lower valuation multiples (forward P/E of 17x vs. RTX's 26.7x) and guaranteed long-term revenue from the F-35 program extending into the 2040s, despite RTX showing faster expected growth and lower debt levels.

XORTX Therapeutics Inc. has elected to voluntarily delist its common shares from the TSX Venture Exchange (TSXV) to reduce costs and administrative burden. The company will maintain its listings on Nasdaq and Frankfurt. The delisting is expected to eliminate duplicative exchange fees, reduce legal and accounting expenses, and allow management to focus on advancing its XRx-026 gout treatment program. Canadian shareholders will retain full trading access on Nasdaq.

SpaceX's upcoming IPO values the company at $1.77 trillion, exceeding the combined valuation of all 12 S&P 500 aerospace and defense companies (~$1.5 trillion), despite generating only $18.7 billion in revenue compared to their $500 billion combined. While analysts like Gene Munster and Ron Baron express bullish sentiment with predictions of $30 trillion future value, critics including NYU's Aswath Damodaran raise concerns about valuation and market opportunity estimates.

Nvidia unveiled the RTX Spark, a superchip combining Blackwell RTX graphics, Arm CPU cores, and an NPU for personal computers, marking the company's entry into the PC market. The chip delivers petaflop AI computing power and unified memory for local AI applications. Analysts view this as part of Nvidia's broader strategy to dominate AI across all layers—data centers, edge, PCs, and IoT—with strong revenue growth expected and price targets reaching $500 within 12 months.

ASUS unveiled its new ProArt P16 and P14 laptops along with a ProArt Mini PC powered by NVIDIA's RTX Spark superchip at Computex 2026. These devices are designed for AI creators and developers, featuring up to 1 petaflop of AI performance, 128GB unified memory, and ASUS Lumina Pro OLED displays. The ecosystem integrates exclusive AI tools and partnerships with Adobe, Blackmagic Design, and Blender. Availability begins fall 2026.

MediaTek and NVIDIA announced a collaboration on the RTX Spark, a new processor class for Windows 11 PCs designed for personal AI agents, content creation, and gaming. MediaTek contributes CPU performance, power efficiency, memory architecture, and connectivity expertise, while NVIDIA provides its AI platform and RTX technologies. The first RTX Spark-powered laptops will launch in Fall 2026, marking MediaTek's expansion from entry-level devices into the premium Windows PC market.

HP Inc. unveiled a comprehensive portfolio of AI-enabled devices and solutions designed for developers, creators, and gamers. The announcement includes laptops powered by NVIDIA RTX Spark, the HP OmniDesk Mini Desktop PC with Thunderbolt Share, secure AI processing systems for regulated environments, and workstations featuring AMD Ryzen AI PRO processors. These devices aim to accelerate local AI processing and hybrid workflows while maintaining security and ease of setup.

BioRestorative Therapies announced completion of dosing in its Phase 2 clinical trial for BRTX-100, treating 99 patients with chronic lumbar disc disease. The randomized, double-blind, sham-controlled study has advanced to blinded follow-up with topline safety and efficacy data expected in Q2 2027. The company received FDA alignment on Phase 3 development pathway following a Type B meeting, with no clinical safety concerns raised.

China banned Nvidia's RTX 5090D V2 chip, signaling a shift toward reducing dependency on U.S. semiconductors and favoring domestic alternatives. While the U.S. approved H200 sales to Chinese tech companies, no chips have been delivered due to undisclosed conditions from Beijing. Nvidia's China revenue has fallen to 5% of total sales, and the ban suggests the company's export-compliant strategy has failed at both ends—Washington restricts high-end chips while Beijing blocks lower-end alternatives.